Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Nov 25, 2022 4:20pm
159 Views
Post# 35129059

RE:RE:RE:RE:RE:RE:RE:RE:RE:Momentum forward

RE:RE:RE:RE:RE:RE:RE:RE:RE:Momentum forwardalas westcoast, I'm a long term shareholder, since 2004. Through trading the stock I've changed a 95% loss prior to release of IND-213 data, to what is now a 50% loss.

And my core holding have occasionally been in the green... but usually only for a day or two... no stock runs are ever sustained.

And NO,  I'm not here to bash... I'm here to question... and generate discussion points. Like HOW do you value this company... it has diminishing funds, expiring patents, and trials that last years longer than shareholders were originally told.. I went in heavy on this stock follow the wisdom of pumpers, and my own blind greed.

It was a bitter lesson. And I get angry seeing other pumping this company to the moon as though it is a home run aready. It is NOT. How do we (you) know how good the Bracelet-1 data is... if it is no better than that from IND-213, ONCY will have wasted 5 years and we still don't have a partner...

Concerns about AN not even listing Pela in the their pipeline should mean something... WHY ?  Do you have a reasonable answer.?

And no, I would only encourage others to buy, if I thought this was a sure fire home run... it's not, it's a thinly traded stock that exists on the edge of being tossed off the Nasdaq yet again... you want another reverse split ???

Until we have CONCLUSIVE and UNASSAILABLE data that PROVES PELA + CPI + Pax in mBC is better Pela+Pax alone, then we will sit in sh*t'sville pps wise.

Every run gets sold into, so investors must tread carefully.. But for some simple minded folk it's just easier to think any contrary opinion is the work of a paid cabal... conspiracy theory, faked moon landings, Covid etc etc... 

GLTA (with some exceptions)
<< Previous
Bullboard Posts
Next >>